| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K29313308 | CTRPv2 | pan-cancer | AAC | -0.067 | 0.1 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.065 | 0.1 |
| mRNA | PLX4720 | GDSC1000 | pan-cancer | AAC | -0.06 | 0.1 |
| mRNA | Docetaxel | CTRPv2 | pan-cancer | AAC | -0.095 | 0.1 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | -0.064 | 0.1 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | -0.063 | 0.1 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | 0.13 | 0.1 |
| mRNA | selumetinib:piperlongumine (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.063 | 0.1 |
| mRNA | piperlongumine | GDSC1000 | pan-cancer | AAC | 0.064 | 0.1 |
| mRNA | foretinib | CTRPv2 | pan-cancer | AAC | -0.063 | 0.1 |